OR WAIT null SECS
July 17, 2019
Abcam has acquired the entire live cell line and lysates portfolio of gene-editing therapy developer, EdiGene.
July 16, 2019
Boehringer Ingelheim will combine assets from its cancer immunology portfolio with the KISIMA immunization platform from AMAL Therapeutics.
Gilead Sciences gains rights to clinical and preclinical programs in Galapagos’ portfolio through a 10-year global research and development collaboration.
Kite, a Gilead company, announced plans to build a new facility for the development and manufacturing of the starting material for the production of cell therapies, viral vectors.
July 12, 2019
Oncology drug discovery and development company, ADC Therapeutics, has closed its Series E financing expansion, in which it raised $103 million.
July 03, 2019
Fresenius Kabi recalls chemotherapy drug because of possible glass particulate within the drug vials.
Metabolic-disease biotech Amicus Therapeutics announced a manufacturing agreement with Catalent’s Paragon Gene Therapy unit for gene therapy manufacturing.
July 02, 2019
Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.
July 01, 2019
The companies will join forces to develop new immuno-oncology therapies in a deal worth up to $470 million.
FDA approved first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system.